3 May 2022 ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University
28 March 2022 ORYZON announces appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and continues its expansion of US corporate activities